Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-arm Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects With Lumbosacral Radiculopathy

Next Previous
Trial Profile

An Open-label, Single-arm Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects With Lumbosacral Radiculopathy

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Sciatica
  • Focus Pharmacodynamics; Registrational
  • Sponsors Scilex Holding; Semnur Pharmaceuticals

Most Recent Events

  • 26 Mar 2019 According to a Sorrento Therapeutics Media Release,Dr. Richard Radnovich is the principal investigator of this study.
  • 26 Mar 2019 According to a Sorrento Therapeutics Media Release, this study was conducted as a part of the FDA requirements for NDA submission, to characterize repeat dose pharmacodynamics (PD) with respect to hypothalamic-pituitary-adrenal (HPA) suppression using plasma cortisol levels, white blood cell count (WBC), and blood glucose levels.
  • 26 Mar 2019 Results published in the Sorrento Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top